Indication

Pembrolizumab in combination with lenvatinib, for the treatement of advanced or recurrent endometrial carcinoma (EC) in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2474
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
10 October 2022
SMC meeting date:
06 September 2022
Patient group submission deadline:
04 July 2022